Caratuberside

Caratuberside: A Comprehensive Encyclopedic Reference

1. Identity and Chemical Characterization

1.1 Nomenclature and Chemical Classification

Caratuberside is the collective name given to a series of closely related pregnane glycosides — steroidal natural products built on a pregnane (C-21 steroid) carbon skeleton to which one or more sugar units are attached. The individual congeners are designated caratuberside A, B, C, D, E, F, and G, as well as the structural variant caratuberside A2. The molecular structures of two foundational members of the series, caratuberside A and caratuberside B, were determined and published by Ahmad et al. in the Journal of Natural Products in 1988. Subsequent work extended the series through additional congeners. A report on the possible biosynthetic pathway of pregnane glycosides and isolation of caratuberside A–G was presented by Rizwani, Usmanghani, Ahmad, and colleagues at the First National Conference on Biochemistry in 1992.

The compound caratuberside A has been registered in the chemical literature with the molecular formula C₃₄H₅₆O₁₂, as catalogued in the PubChem chemical database under CID 138393966. Its full structural entry, including chemical names, physical and chemical properties, classification, literature, and biological activities, is maintained in PubChem.

The sugar moiety of caratuberside A from Caralluma tuberculata was identified by Ahmad et al. using spin couplings in the COSY-45 NMR experiment, with the sequence of sugars in the glycoside deduced from long-range correlations. The broader caratuberside series share the distinctive structural features of pregnane-type glycosides found throughout the family Asclepiadaceae (now placed within Apocynaceae): a steroidal aglycone (genin) carrying hydroxyl and/or acyl substituents at various ring positions, with an oligosaccharide chain attached typically at the C-3 position.

1.2 Botanical Source

Caratubersides are the characteristic secondary metabolites of Caralluma tuberculata N. E. Brown, a succulent leafless herb belonging to the subfamily Asclepiadoideae of the family Apocynaceae (historically classified under Asclepiadaceae). C. tuberculata is a herb distributed in dry regions of the world; the succulent stem of the plant is widely used to treat several ailments.

Botanically, it is a cactus-like herb that grows in the deserts of Pakistan and India; the stems are fleshy, edible, and quadrangular, while the leaves are minute and ephemeral. It is a native, critically endangered plant of Pakistan, but can also be found in various dry, arid areas of Asia, Africa, and southeast Europe.

Caratubersides are also found, in some instances, in related Caralluma species and allied genera of the Asclepiadoideae. Natural pregnane glycosides are mainly distributed in the genus Caralluma and Cynanchum of Asclepiadaceae; these plants mainly grow in arid areas such as India, Arabia, and southwest China. Structural relatives of the caratuberside series — including caratubersides B and D — have been isolated from more distantly related species such as Caralluma awdeliana from Yemen, indicating some taxonomic breadth for these compounds within the genus. In that study, repeated chromatography of a DCM fraction resulted in the isolation of two known pregnane glycosides, namely caratubersides B and D, along with flavone glycosides.

1.3 Co-occurring Phytochemicals

Caratubersides occur alongside a rich array of other secondary metabolites in C. tuberculata. Secondary metabolites isolated from the plant include terpenes (lupeol, α- and β-amyrin, α-amyrin acetate, α-amyrin cinnamate), pregnanes (caratuberside A, B, C, D, E, F, and G), sterols (β-sitosterol and its glucoside, taraxasterol), and flavonoids (luteolin glycoside and glycosides of kaempferol). It also contains cardiac glycosides, acylated steroidal glycosides, coumarin, emodins, anthocyanin, betacyanin, alkaloids, tannins, several reducing sugars, essential oils, hydrocarbons, and other fatty acids.

Among caratubersides specifically, russelioside B, russelioside C, and caratuberside C have been quantified in methanolic extracts by LC-MS. Russelioside B, russelioside C, and caratuberside C are present in amounts of 239, 12.8, and 42.8 mg per gram of methanol extract, respectively.

1.4 Common Forms and Commercial Preparations

In the dietary supplement marketplace, caratubersides appear primarily as components of standardized Caralluma fimbriata (closely related species) or C. tuberculata extracts. Caratuberside-bouceroside found in Caralluma species has a cardiac binding ratio (CBR) of glycoside content that belongs to the pregnane group. Commercially available preparations are most commonly standardized hydroethanolic or methanolic dry extracts encapsulated in capsule or tablet form. One branded extract (Slimaluma™) is derived from Caralluma fimbriata and standardized to a defined percentage of pregnane glycosides including caratubersides. Caralluma supplements demand precise standardization to pregnane glycosides for consistent efficacy; manufacturing partners must verify active compound levels through validated analytical methods, and standardization to 10–25% pregnane glycosides ensures therapeutic consistency.

Pregnane glycosides including caratuberside compounds provide appetite-modulating effects, and Caralluma also contains flavonoids, which are natural antioxidants that support metabolism and contribute to its health benefits. Liquid extracts and raw dried plant material (powdered stem) are also documented, primarily in traditional contexts rather than commercial supplement markets.

2. Traditional and Historical Use

2.1 Geographic and Cultural Contexts

Caralluma tuberculata and its caratuberside-containing stem have been integral to traditional medicine across arid regions of the Indian subcontinent, particularly in Pakistan (including Balochistan, Khyber Pakhtunkhwa, and the tribal areas of FATA) and northwestern India. The succulent stem of the plant is widely used in traditional practice to treat several ailments including diabetes, rheumatism, leprosy, peptic ulcer, inflammation, jaundice, dysentery, constipation, stomach pain, and hepatitis B and C.

The closely related species Caralluma fimbriata, whose extracts are standardized to caratubersides in the supplement industry, has a comparable traditional background in India, especially among tribal communities in Andhra Pradesh, Rajasthan, and other states. Caralluma fimbriata is an edible cactus used by tribal Indians to suppress hunger and enhance endurance.

Ethnobotanical surveys in the tribal Mohmand Agency region of Pakistan recorded the highest use reports for C. tuberculata (49 URs), placing it at the top of all medicinal plants documented in that study. The significance of this high use-report frequency underscores the depth of the plant's integration into local healthcare traditions.

2.2 Modes of Traditional Preparation

Wild and cultivated C. tuberculata in Pakistan is traditionally used in the form of tea to cure diabetes. The whole plant is also dried and ground to powder, which is taken with water for dysentery, stomach pain, constipation, and gastric problems. The plant can also be utilized as a cooked vegetable, added to tea, used as a dry powder, or chewed raw. The plant is consumed as a vegetable and is considered an antidiabetic agent due to its bitter taste.

In Quetta, Pakistan, there is a tradition for treating high blood pressure by chewing the fresh plant. The stem of C. tuberculata and the related C. edulis is cooked as a food with minced meat and considered effective in digestion. The endemic C. attenuata, locally known as "Kundaetikommu," is eaten raw to cure diabetes in several districts of Andhra Pradesh, India, and the same plant is cooked as fresh food and used against diabetes and high blood pressure.

2.3 Purposes of Traditional Use

Across its range of traditional use, the primary documented purposes of C. tuberculata (and thus, of its caratuberside content) include: appetite suppression during famines or hard travel; management of diabetes and hyperglycemia; treatment of gastrointestinal complaints (dysentery, constipation, stomach pain, peptic ulcer); management of inflammatory conditions including rheumatism; treatment of skin infections and leprosy; liver-related conditions (jaundice, hepatitis); and fever reduction. Several members of the genus Caralluma have found medicinal uses in the treatment of rheumatism, diabetes, and leprosy, and as antiseptics and disinfectants.

Conservation concerns have arisen alongside commercial demand. Afghan refugees in the Waziristan region of Pakistan are collecting C. tuberculata unsustainably from the wild and selling it into local markets; plants are then exported to city markets where the selling price is sixfold higher, and the plant has been documented as a highly threatened species in the northwest region of Pakistan. Destructive harvesting for ethnomedicinal purposes generally results in species extinction from its natural habitat.

3. Key Constituents and Active Compounds

3.1 The Caratuberside Series: Structural Overview

The caratuberside series represents a structurally complex group of polyoxygenated pregnane glycosides. The pregnane aglycone skeleton (a 21-carbon steroid closely related to progesterone in its core ring system) bears multiple hydroxyl and/or acyl groups at various positions, conferring both biological activity and bitter taste. The sugar chains, which distinguish the individual congeners (A through G), typically consist of one to several monosaccharide units attached at the C-3 position of the steroid nucleus. The sugar of caratuberside A from C. tuberculata was identified by Ahmad et al. using spin couplings in the COSY-45 NMR experiment, with information on the sequence of sugars deduced from long-range correlations.

Various pregnane glycosides have been isolated from the whole plant of Caralluma tuberculata; monodesmoside-type pregnane glycosides possess an oligosaccharide chain at C-3 of the aglycone consisting of one to six sugar units. It can be concluded that the bioactivities of pregnane glycosides are obviously related to their structural types, and natural pregnane glycosides are a large group of compounds with diverse structures and versatile biological activities, with cytotoxic activities particularly prominent.

Structure-activity relationship studies conducted on related Caralluma pregnane glycosides have found that the presence and type of acyl groups are especially important. It was noticed that acylation is required for the antitrypanosomal activity of caratuberside-related compounds, while glycosylation at C-20 has no significant effect on this particular activity. This finding suggests that different structural features of the caratuberside skeleton modulate different biological effects.

3.2 Proposed Mechanisms of Action

Caratubersides, like other Caralluma pregnane glycosides, are thought to exert their primary biological effects through several proposed — but not all definitively established — mechanisms:

• Inhibition of fat biosynthesis: The plant contains pregnane glycosides, a group of naturally occurring compounds known to inhibit fat formation, thereby assisting in reducing central adiposity, a major factor contributing to metabolic syndrome, hypertension, and cardiovascular diseases.
• Antidiabetic mechanisms: The mechanisms of the bioactive secondary metabolites include lowering the blood glucose level, stimulating B cells of the pancreas to release more insulin, enhancing the sensitivity of the insulin receptor, inhibiting the action of glucagon and the hydrolysis of glycogen, and increasing the use of glucose in tissues and organs. Anti-hyperglycemic effects include competitive inhibition of α-amylase and α-glucosidase by binding to glucose transporters; additionally, terpenoids, saponins, gallic acid, and ferulic acid could increase insulin secretion and accelerate the uptake and utilization of glucose, improving the performance of the pancreatic tissue and reducing intestinal absorption.
• Cytotoxicity / pro-apoptotic activity: Pregnane glycosides are potent cytotoxic agents which may represent new leads in the development of anti-tumour drugs, particularly in the treatment of breast cancer, because of their structural similarity to estrogenic agonists; Caralluma species are natural sources of a wide variety of pregnane glycosides.
• Antiparasitic activity: The pregnane-type saponin caratuberside C was lethal for Trypanosoma brucei brucei (GUTat 3.1 strain) and P. falciparum (K1) with IC₅₀ values of 1.8 and 7 µg/mL, respectively.
• Enzyme inhibition related to diabetes/lipid metabolism: LC-MS analysis of the methanolic extract of C. tuberculata identified compounds including russelioside B, russelioside C, and caratuberside C; previous reports suggest that such metabolites enhance lipid uptake, improve glucose absorption, and regulate blood sugar.

A patent covering the use of pregnane glycosides including caratubersides in obesity treatment describes a preferred formulation ratio. Preferably, the ratio of caratuberside and bouceroside in compositions for such uses is from 9:1 to 19:1 by weight.

4. Scientific Evidence by Area of Use

4.1 Appetite Suppression and Weight Management

This is the area with the most direct clinical investigation, though the evidence base applies principally to caratuberside-containing extracts (whole-plant or standardized extracts of C. fimbriata), rather than to isolated caratuberside compounds specifically.

Clinical study (Kuriyan et al., 2007): The effect of Caralluma extract was assessed in overweight individuals by a placebo-controlled randomized trial in which 50 adult men and women (25–60 years) with a BMI greater than 25 kg/m² were randomly assigned to a placebo or experimental group; the latter received 1 g of Caralluma extract per day for 60 days, with all subjects given standard advice regarding a weight-reducing diet and physical activity. Waist circumference and hunger levels over the observation period showed a significant decline in the experimental group when compared to the placebo group; while there was a trend toward a greater decrease in body weight, BMI, hip circumference, body fat, and energy intake in the experimental group, these were not significantly different between groups. Overall, Caralluma extract appeared to suppress appetite and reduce waist circumference compared to placebo over a two-month period.

Clinical study (negative outcome): A prospective, randomized, placebo-controlled trial evaluated the efficacy and safety of commercially available CFE in overweight and obese individuals; 89 patients were randomized into a treatment group (n = 47) and placebo group (n = 42) to receive either CFE capsules 500 mg twice daily for 12 weeks or matching placebo. At the end of the study period, both CFE and placebo caused only numerical reduction in weight, BMI, waist circumference, hip circumference, and waist-hip ratio; CFE in an oral dose of 1 g/day failed to yield any positive results on anthropometry and appetite beyond placebo, with no significant differences in clinical and biochemical parameters, though CFE was well tolerated, underscoring the need for more research before CFE is recommended as an anti-obesity drug.

Systematic review and meta-analysis (Jayawardena et al., 2021): Clinical trials present mixed results, with modest benefits in central obesity and caloric intake reduction, but limited impact on anthropometric and metabolic parameters, underscoring the need for long-term, large-scale studies; toxicological assessments indicate a high safety margin.

Evidence strength: Weak to preliminary for caratuberside-containing extracts as appetite suppressants. Individual trials are small, short in duration, and report inconsistent outcomes. No study has tested isolated caratuberside compounds in humans. The overall evidence does not support definitive efficacy conclusions.

4.2 Antidiabetic and Blood Glucose Effects

Caralluma tuberculata, a medicinal and edible plant of the genus Caralluma, has traditionally had its succulent stems used as folk medicine for diabetes mellitus; its antidiabetic potential is ascribed to the presence of various secondary metabolites including pregnane glycosides, flavone glycosides, megastigmane glycosides, polyphenols, ferulic acid, quercetin, and bitter principles.

In vivo evidence: A study published in Food and Chemical Toxicology (Abdel-Sattar et al., 2013) reported antihyperglycemic activity of C. tuberculata extracts in streptozotocin-induced diabetic rats. Antihyperglycaemic and hypolipidaemic effects of the methanolic extract of C. tuberculata in streptozotocin-induced diabetic rats were published in Natural Product Research, 2011.

Molecular docking (in silico): LC-MS analysis of the methanolic extract of C. tuberculata identified compounds including russelioside B, russelioside C, and caratuberside C, with previous reports suggesting such metabolites enhance lipid uptake, improve glucose absorption, and regulate blood sugar; this study's findings hold potential as significant antidiabetic agents and offer valuable bioactive resources for pharmaceutical applications.

Evidence strength: Preclinical only (animal models and in silico). No controlled human clinical trials specifically investigating caratubersides' antidiabetic effects have been identified in the peer-reviewed literature. Evidence is preliminary.

4.3 Anticancer and Cytotoxic Activity

In vitro research (Waheed et al., 2011): The aim of the study was to isolate, using an activity-guided fractionation approach, novel pregnane glycosides for testing on breast cancer and other tumour lines; the effect of crude extracts, specific organic fractions, and isolated compounds from C. tuberculata was tested on MCF-7 estrogen-dependent and MDA-MB-468 estrogen-independent breast cancer cells, Caco-2 human colonic cells, HUVECs, and U937 cells using neutral red uptake and MTT assays; the ethyl acetate fraction was found to be the most potent antiproliferative fraction against all three cancer cell lines, and two novel steroidal glycosides were isolated from the active fraction. Two novel steroid glycosides isolated from C. tuberculata were concluded to possess moderate, micromolar cytotoxic activity on breast cancer and other cells in vitro, which may indicate a source of activity in vivo of interest to future drug design.

Evidence strength: In vitro only. No animal or human studies have tested caratuberside compounds specifically for anticancer efficacy. Results are of scientific interest but are far from clinical application.

4.4 Antiparasitic Activity

In vitro research: Pregnane glycosides previously isolated from the genus Caralluma (including from C. tuberculata) were tested for antitrypanosomal activity; caratuberside C showed an IC₅₀ of 1.85 µg/mL and exhibited the highest selectivity index (SI 12.04) among the compounds tested, and it was found that acylation is required for antitrypanosomal activity while glycosylation at C-20 has no significant effect. All isolated compounds were also tested for antimalarial and antitrypanosomal activities as well as their cytotoxicity against a human diploid embryonic cell line (MRC5).

Evidence strength: In vitro only. All antiparasitic data are from cell-based assays. No in vivo or human studies have been conducted using isolated caratuberside compounds for parasitic diseases. The in vitro selectivity data are of mechanistic interest only at this stage.

4.5 Antioxidant and Anti-inflammatory Properties

Caralluma fimbriata is rich in diverse phytochemicals including pregnane glycosides, flavonoids, saponins, steroids, and phenolic compounds, which support its broad spectrum of pharmacological activities, including antioxidant and anti-inflammatory effects. The plant is documented to possess beneficial effects as antihyperglycemic, antibacterial, antifungal, antinociceptive, and antiproliferative agents.

Evidence strength: Preclinical (in vitro and animal model). These effects have not been tested in human clinical trials focusing on caratuberside compounds specifically.

5. Body Systems and Health Areas of Association

• Metabolic system / adipose tissue: Appetite suppression, fat biosynthesis inhibition, central adiposity reduction (predominantly via pregnane glycoside class including caratubersides).
• Endocrine / glycemic regulation: Blood glucose lowering, insulin secretion stimulation, insulin receptor sensitization, inhibition of carbohydrate-digesting enzymes.
• Oncology (exploratory): In vitro cytotoxicity against breast cancer (MCF-7, MDA-MB-468), colonic cancer (Caco-2), and other cell lines; caspase-dependent apoptosis induction.
• Parasitology (exploratory): In vitro activity against Trypanosoma brucei brucei and Plasmodium falciparum.
• Digestive system: Traditional use for dysentery, constipation, stomach pain, peptic ulcer, and general gastric complaints; limited preclinical pharmacological investigation.
• Musculoskeletal / inflammatory: Traditional use for rheumatism and inflammation; antinociceptive and anti-inflammatory activity reported in preclinical settings for related Caralluma flavonoids.

6. Dosage Forms and Reported Dosages

All dosages described below are drawn directly from published sources and should not be interpreted as endorsements or recommendations.

• Human clinical trial (Kuriyan et al., 2007): Fifty adult men and women (25–60 years) with a BMI greater than 25 kg/m² received 1 g of Caralluma extract per day for 60 days.
• Human clinical trial (randomized controlled, 2015): A total of 89 patients were randomized to receive either CFE in the form of capsules 500 mg twice daily (total 1 g/day) for 12 weeks or matching placebo.
• Animal chronic toxicity study: No deaths or treatment-related toxicity were seen in a 6-month chronic oral toxicity study in Sprague-Dawley rats conducted at three doses (100, 300, and 1000 mg/kg body weight per day); the no observed effect level for CFE was considered to be 1000 mg/kg bw/d.
• Animal prenatal developmental toxicity study: A prenatal developmental toxicity study in female Sprague-Dawley rats was conducted at three doses (250, 500, and 1000 mg/kg bw/d).
• Supplement industry standardization: Dosage calculations in supplement manufacturing align with clinical studies using 500–1000 mg daily. Standardization is typically expressed as a percentage of total pregnane glycosides, of which caratubersides form a subset.

Dosage forms in the supplement industry include encapsulated dry extract (capsules and tablets), with the raw plant material also available as powder in traditional contexts.

7. Safety Considerations and Interactions

7.1 Toxicological Profile

The most comprehensive toxicological evaluation of a standardized caratuberside-containing extract (a hydroethanolic extract of Caralluma fimbriata, CFE) was published in the International Journal of Toxicology (Odendaal et al., 2013). This assessment evaluated the safety of a hydroethanolic extract from Caralluma fimbriata (CFE); studies included two in vitro genotoxicity assays, a repeated-dose oral toxicity study, and a developmental study in rats; no evidence of in vitro mutagenicity or clastogenicity was found at concentrations up to 5000 µg of extract/plate (Ames test) or 5000 µg of extract/mL (chromosomal aberration test). No deaths or treatment-related toxicity were seen in the 6-month chronic oral toxicity study in Sprague-Dawley rats at three doses (100, 300, and 1000 mg/kg bw/d), and the no observed effect level (NOEL) for CFE was considered to be 1000 mg/kg bw/d.

Toxicological assessments indicate a high safety margin for CFE, with a NOAEL of 1000 mg/kg/day in animals and only mild, transient gastrointestinal effects in humans at recommended doses.

Long-term safety data for Caralluma extracts remain limited and require further research.

7.2 Human Tolerability Data

In the randomized controlled trial evaluating CFE at 1 g/day for 12 weeks, CFE was well tolerated, though the study underscored the need to carry more research before CFE is recommended as an anti-obesity drug.

7.3 Genotoxicity

Studies in the genotoxicity assessment included two in vitro genotoxicity assays; no evidence of in vitro mutagenicity or clastogenicity surfaced at concentrations up to 5000 µg of extract/plate (Ames test) or 5000 µg of extract/mL (chromosomal aberration test).

7.4 Developmental Toxicity

A prenatal developmental toxicity study in female Sprague-Dawley rats at three doses (250, 500, and 1000 mg/kg bw/d) resulted in no treatment-related external, visceral, or skeletal fetal abnormalities. No human pregnancy safety data exist for caratuberside-containing extracts.

7.5 Conservation Status and Supply-Chain Considerations

Caralluma tuberculata has been documented as a highly threatened species in the northwest region of Pakistan; Indian Caralluma species are also considered threatened due to agricultural extension and population pressure. Unsustainable wild harvesting driven by supplement demand poses a real ecological risk, as noted in ethnobotanical literature. Destructive harvesting for ethnomedicinal purposes generally results in species extinction from the plant's natural habitat.

7.6 Quality and Adulteration Risks

Because caratubersides are the marker compounds used for standardization of Caralluma extract products, accurate determination of their content is critical for product quality assurance. Quality systems should authenticate botanical identity to prevent adulteration; all batches should be tested for quality and manufactured in compliance with industry standards.

8. Summary of Evidence Gaps

The scientific evidence base for caratubersides as isolated, characterized compounds remains substantially preclinical. While the plant sources from which they derive have an extensive tradition of use and a modest body of clinical research (primarily for appetite suppression), the following limitations apply to the current state of knowledge:

• No randomized controlled clinical trials have been conducted using isolated and characterized caratuberside compounds (as opposed to whole or partially standardized plant extracts).
• All anticancer, antiparasitic, and most antidiabetic data derive from in vitro or animal experiments.
• Clinical trials on Caralluma extracts present mixed results, with modest benefits in central obesity and caloric intake reduction, but limited impact on anthropometric and metabolic parameters, underscoring the need for long-term, large-scale studies.
• Mechanism-of-action data, while suggestive, require confirmation in validated human physiological models.
• Long-term human safety data, particularly for vulnerable populations, remain absent from the published literature.

References

• PubChem: Caratuberside A | CID 138393966
• Ahmad et al. (1988). New Pregnane Glycosides from Caralluma tuberculata. Journal of Natural Products, 51(6), 1092–1097.
• Abdel-Sattar et al. (2008). Acylated pregnane glycosides from Caralluma tuberculata and their antiparasitic activity. Phytochemistry, 69(11), 2180–2186.
• Abdel-Sattar et al. (2009). Antitrypanosomal activity of some pregnane glycosides isolated from Caralluma species. Phytomedicine, 16(6–7), 659–664.
• Waheed A et al. (2011). Novel acylated steroidal glycosides from Caralluma tuberculata induce caspase-dependent apoptosis in cancer cells. Journal of Ethnopharmacology, 137(3), 1189–1196.
• Odendaal AY et al. (2013). Safety assessment of a hydroethanolic extract of Caralluma fimbriata. International Journal of Toxicology, 32(5), 385–394.
• Kuriyan R et al. (2007). Effect of Caralluma fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women. Appetite, 48(3), 338–344.
• Aslam M et al. (2015). To evaluate efficacy and safety of Caralluma fimbriata in overweight and obese patients: a randomized, single blinded, placebo control trial. Journal of Pharmacy & Bioallied Sciences.
• Jayawardena R et al. (2021). The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials. BMC Complementary Medicine and Therapies, 21(1), 279.
• Bashir T & Haider S (2015). Ethnomedicinal and pharmacological properties of Caralluma tuberculata N. E. Brown – A review. Pure and Applied Biology, 4(4), 503–510.
• Adnan M et al. (2014). A review on ethnobotany, phytochemistry and pharmacology of plant genus Caralluma R. Br. Journal of Pharmacy and Pharmacology, 66(10), 1351–1368.
• Ali A et al. (2022). Plant in vitro cultures: A promising and emerging technology for the feasible production of antidiabetic metabolites in Caralluma tuberculata. Frontiers in Endocrinology, 13, 1029942.
• PLOS ONE (2024). Elucidating the binding mechanism of Caralluma tuberculata metabolites with type 2 diabetes targets through molecular docking and dynamics simulations.
• Abdel-Sattar E et al. (2022). Russelioside B: a pregnane glycoside with pharmacological potential. Revista Brasileira de Farmacognosia.
• Aziz MA et al. (2018). Traditional uses of medicinal plants practiced by the indigenous communities at Mohmand Agency, FATA, Pakistan. Journal of Ethnobiology and Ethnomedicine, 14(1), 3.
• PlantUse: Caralluma adscendens (PROTA) — phytochemical and clinical data including caratuberside A-B.
• Choucry MA et al. (2021). New pregnane glycosides isolated from Caralluma hexagona Lavranos as inhibitors of α-glucosidase, pancreatic lipase, and advanced glycation end products formation. ACS Omega, 6(29), 18881–18889.
• Abdel-Sattar E et al. (2025). Genus Caralluma in Yemen: A comprehensive review of taxonomy, ethnomedicine, phytochemistry, and biological activities. Chemistry & Biodiversity.
• EP1763359B1 — Use of pregnane glycosides in the treatment/management of obesity (European Patent).
• Caralluma Fimbriata: An Emerging Nutraceutical Source With Multifunctional Health Benefits (Academic Review).